<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568033</url>
  </required_header>
  <id_info>
    <org_study_id>13-130</org_study_id>
    <nct_id>NCT02568033</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer</brief_title>
  <official_title>Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer (Protocol Number GK001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cooper Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cooper Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study looking at using stereotactic radiosurgery and full dose chemotherapy&#xD;
      to treat stage II and III lung cancer that is not amendable to surgical resection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current standard of care for treatment of locally advanced (unresectable stage II and all of&#xD;
      stage III) non-small cell lung cancer (NSCLC) is chemo-radiation which consists of 7 weeks of&#xD;
      radiation and chemotherapy given at a reduced dose (as opposed to systemic dose when&#xD;
      chemotherapy given by itself). While outcomes have improved over time they remain humbling,&#xD;
      with current approaches associated with overall poor results both in terms of local (30% of&#xD;
      patients have local failure) and distant control (40% of patients have distant failure) with&#xD;
      a median overall survival of 17 months.&#xD;
&#xD;
      This study is evaluating treatment with full dose chemotherapy and stereotactic body&#xD;
      radiotherapy (SBRT). SBRT uses high doses of radiation in a very precise and conformal&#xD;
      manner, the number of treatments are much reduced versus conventional radiation (SBRT would&#xD;
      be able to be completed in 2 weeks or less). The biologically effective dose of SBRT is much&#xD;
      higher than that of conventional radiation; despite being a shorter number of treatments the&#xD;
      effective radiation dose is higher. SBRT would be completed in 2 weeks and since radiation&#xD;
      would be completed in a shorter time span, would allow patients to have higher (systemic)&#xD;
      chemotherapy doses.&#xD;
&#xD;
      The purpose of this study is to explore SBRT in addition to systemic doses of chemotherapy in&#xD;
      the treatment of locally advanced NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free progression</measure>
    <time_frame>4-6 months</time_frame>
    <description>Local control will be evaluated at end of treatment (4-6 months) and then at regular follow up intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity (Treatment related side effects)</measure>
    <time_frame>4-5 months</time_frame>
    <description>Treatment related side effects will be monitored</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy:&#xD;
for Non-Squamous Cell: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of 21 day cycle or Carboplatin AUC6 and Paclitaxel 75 mg/m2 on day 1 of 21 day cycle&#xD;
for Squamous Cell: Cisplatin 75 mg/m2 and docetaxel 75mg m2 day 1 of 21 day cycle or Carboplatin AUC6 and paclitaxel 200 mg/m2 day 1 of 21 day cycle&#xD;
Radiation- Stereotactic radiosurgery Peripheral Lung lesion: 60 Gy over 3 fractions Central Lung lesion: 50 Gy over 5 fractions Hilar and Mediastinal LNs 40-50Gy over 5 fractions&#xD;
Schedule is:&#xD;
2 cycles of chemotherapy, followed by SRS, followed by 2 additional cycles of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>A</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>A</arm_group_label>
    <other_name>taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>A</arm_group_label>
    <other_name>taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
    <arm_group_label>A</arm_group_label>
    <other_name>CK, cyberknife, cyber knife</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Nonsmall cell lung cancer (NSCLC) (any histology)&#xD;
&#xD;
          -  unresectable stage II&#xD;
&#xD;
          -  Stage III&#xD;
&#xD;
          -  Tumor less than 8 cm&#xD;
&#xD;
          -  Karnofsky performance scale (KPS) of 50 or better&#xD;
&#xD;
          -  Three or fewer mediastinal or hilar lymph nodes&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Small cell lung cancer (SCLC)&#xD;
&#xD;
          -  Stage I and stage IV patients&#xD;
&#xD;
          -  Stage II patients eligible for surgical resection&#xD;
&#xD;
          -  Concurrent severe disease that the treating physician feels will interfere with&#xD;
             therapy this can include significant cardiovascular or pulmonary disease.&#xD;
&#xD;
          -  KPS 40 or less (bed bound)&#xD;
&#xD;
          -  Tumor size greater than 8 cm&#xD;
&#xD;
          -  Inability to safely treat target lesions (at discretion of treating physician, this&#xD;
             would most likely be secondary to not being able to place fiducial markers for&#xD;
             tracking)&#xD;
&#xD;
          -  Four or more medisatinal or hilar lymph nodes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kimberly Krieger</last_name>
    <phone>856-735-6237</phone>
  </overall_contact>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at Cooper</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Krieger</last_name>
      <phone>856-735-6237</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>October 2, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

